Gregory Tietjen, PhD

Assistant Professor

Departments & Organizations

Surgery: Tietjen Lab | Transplant & Immunology Surgery

Human and Translational Immunology Program

Vascular Biology and Therapeutics Program


Dr. Gregory Tietjen earned his PhD in Biophysics at the University of Chicago before completing Postdoctoral training in the Department of Biomedical Engineering at Yale University. At all levels of his training, Dr. Tietjen’s emphasis has been on integrating multiple diverse disciplines to forge new scientific pathways. Dr. Tietjen is now excited to apply his expertise in molecular biophysics and nanotechanology within a clinical context as an Assistant Professor in the Yale School of Medicine Department of Surgery, Section of Transplantation and Immunology. The focus of Dr. Tietjen’s current research is on adapting isolated organ machine perfusion, a recently developed innovation in clinical transplant, for use as a model system to engineer vascular-targeted nanomedicines. The ultimate goal of the Tietjen lab is to use the organ perfusion model to develop new therapeutic paradigms for use in organ transplant, while simultaneously establishing the theoretical 
foundation necessary for anatomic and cellular precision following 
systemic administration of targeted nanomedicines.

Education & Training

PhD University of Chicago, Biophysics (2013)
BS University of Oregon, Physics (2008)
BA Wake Forest University, English (2002)
Postdoctoral Fellow Yale University

Edit this profile

Contact Info

Gregory Tietjen, PhD
Molecularly-Targeted Nanomedicine

The Tietjen lab employs molecularly targeted nanoparticle-based drug carriers as a mechanism to control the cellular and intra-organ distribution of encapsulated therapeutics. We are particularly focused on delivery of immunomodulatory drugs to vascular endothelium.

Isolated Kidney Perfusion System.

Ex vivo organ perfusion has emerged as a valuable clinical strategy to assess and potentially revive marginal organs in solid organ transplantation. These periods of ex vivo perfusion provide an ideal window to deliver therapeutics directly to the graft without concern for unwanted system effects. Working in collaboration with leading transplant clinicians at the University of Cambridge, we have been adapting our vascular targeted nanoparticles for use during ex vivo normothermic perfusion of kidney. In on going work, we are looking to integrate a suite of biophysical tools to allow for realtime, 3D evaluation of nanoparticle accumulation during organ perfusion. Image courtesy of Dr. Sarah Hosgood - University of Cambridge.